Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PI4KA | P42356 | 1/20 | 0.61 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.61 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.61 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.53 |
| ▸ | NSD2 | O96028 | 1/20 | 0.51 |
| ▸ | PKM | P14618 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | HAVCR2 | Q8TDQ0 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 3/20 | 0.46 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL256211 | 0.78 | PI4KA (0.63) | PI4KAPI4K2BPI4K2API4KBSMN1; SMN2 | |
| SCHEMBL25237125 | 0.78 | PI4KA (0.63) | PI4KAPI4K2BPI4K2API4KBSMN1; SMN2 | |
| SCHEMBL21348442 | 0.77 | SMN1; SMN2 (0.58) | PI4KAPI4K2BPI4K2API4KBSMN1; SMN2 | |
| SCHEMBL12826084 | 0.76 | PI4KA (0.61) | PI4KAPI4K2BPI4K2API4KBSMN1; SMN2 | |
| SCHEMBL25605061 | 0.76 | PI4KA (0.61) | PI4KAPI4K2BPI4K2API4KBSMN1; SMN2 | |
| SCHEMBL13510 | 0.76 | PI4KA (0.61) | PI4KAPI4K2BPI4K2API4KBSMN1; SMN2 | |
| SCHEMBL130407 | 0.76 | PI4KA (1.00) | PI4KAPI4K2BPI4K2API4KBSMN1; SMN2 | |
| SCHEMBL12590757 | 0.74 | PI4KA (0.54) | PI4KAPI4K2BPI4K2API4KBSMN1; SMN2 | |
| SCHEMBL21851658 | 0.73 | ALDH1A1 (0.58) | PI4KAPI4K2BPI4K2API4KBSMN1; SMN2 | |
| SCHEMBL20276307 | 0.73 | PI4KA (0.58) | PI4KAPI4K2BPI4K2API4KBSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4731216-A1 | HETEROARYL-AMINE COMPOUNDS AND USE THEREOF AS HDAC6 INHIBITORS | Augustine Therapeutics (BE) | 2026-04-29 | — | — | EP | disclosed |
| US-12421222-B2 | Substituted quinazolines as HDAC6 inhibitors | AUGUSTINE THERAPEUTICS (BE) | 2025-09-23 | — | — | US | disclosed |
| US-20250145604-A1 | COMPOUNDS AND USE THEREOF AS HDAC6 INHIBITORS | AUGUSTINE THERAPEUTICS (BE) | 2025-05-08 | — | — | US | disclosed |
| US-20250051319-A1 | COMPOUNDS AND USE THEREOF AS HDAC6 INHIBITORS | AUGUSTINE THERAPEUTICS (BE) | 2025-02-13 | — | — | US | disclosed |
| WO-2024261329-A1 | HETEROARYL-AMINE COMPOUNDS AND USE THEREOF AS HDAC6 INHIBITORS | AUGUSTINE THERAPEUTICS (BE) | 2024-12-26 | — | — | WO | disclosed |
| EP-4452265-A2 | COMPOUNDS AND USE THEREOF AS HDAC6 INHIBITORS | Augustine Therapeutics (BE) | 2024-10-30 | — | — | EP | disclosed |
| CN-118591375-A | Compounds as HDAC6 inhibitors and uses thereof | 奥古斯汀治疗公司 | 2024-09-03 | — | — | CN | disclosed |
| WO-2023118507-A2 | COMPOUNDS AND USE THEREOF AS HDAC6 INHIBITORS | AUGUSTINE THERAPEUTICS (BE) | 2023-06-29 | — | — | WO | disclosed |
| US-20210347964-A1 | RESIN COMPOSITION AND ELECTRONIC DEVICE | Konica Minolta, Inc. (JP) | 2021-11-11 | — | — | US | disclosed |
| US-9790252-B2 | 2-fluorinated riboses and arabinoses and methods of use and synthesis | CORNELL UNIVERSITY (US) | 2017-10-17 | — | — | US | disclosed |
| US-8829010-B2 | Pyrazolo[3,4-d]pyrimidine compounds and their use as PDE2 inhibitors and/or CYP3A4 inhibitors | PFIZER INC. (US) | 2014-09-09 | — | — | US | disclosed |
| US-8829010-B2 | Pyrazolo[3,4-d]pyrimidine compounds and their use as PDE2 inhibitors and/or CYP3A4 inhibitors | PFIZER INC. (US) | 2014-09-09 | — | — | US | disclosed |
| US-8829010-B2 | Pyrazolo[3,4-d]pyrimidine compounds and their use as PDE2 inhibitors and/or CYP3A4 inhibitors | PFIZER INC. (US) | 2014-09-09 | — | — | US | disclosed |
| US-20140080806-A1 | PYRAZOLO[3,4-D]PYRIMIDINE COMPOUNDS AND THEIR USE AS PDE2 INHIBITORS AND/OR CYP3A4 INHIBITORS | HELAL CHRISTOPHER JOHN (US) | 2014-03-20 | — | — | US | disclosed |
| US-20140080806-A1 | PYRAZOLO[3,4-D]PYRIMIDINE COMPOUNDS AND THEIR USE AS PDE2 INHIBITORS AND/OR CYP3A4 INHIBITORS | HELAL CHRISTOPHER JOHN (US) | 2014-03-20 | — | — | US | disclosed |
| US-20140080806-A1 | PYRAZOLO[3,4-D]PYRIMIDINE COMPOUNDS AND THEIR USE AS PDE2 INHIBITORS AND/OR CYP3A4 INHIBITORS | HELAL CHRISTOPHER JOHN (US) | 2014-03-20 | — | — | US | disclosed |
| WO-2012168817-A1 | PYRAZOLO[3,4-D]PYRIMIDINE COMPOUNDS AND THEIR USE AS PDE2 INHIBITORS AND/OR CYP3A4 INHIBITORS | PFIZER INC. (US) | 2012-12-13 | — | — | WO | disclosed |
| US-20120108535-A1 | 2-FLUORINATED RIBOSES AND ARABINOSES AND METHODS OF USE AND SYNTHESIS | CORNELL UNIVERSITY (US) | 2012-05-03 | — | — | US | disclosed |
| US-6423716-B1 | Nitrogenous heterocyclic compounds | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2002-07-23 | — | — | US | disclosed |
| EP-1067123-A1 | NITROGENOUS HETEROCYCLIC COMPOUNDS | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2001-01-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140080806-A1 | PYRAZOLO[3,4-D]PYRIMIDINE COMPOUNDS AND THEIR USE AS PDE2 INHIBITORS AND/OR CYP3A4 INHIBITORS | PDE12, PDE2A, CYP1A2 | PI4KA 291/4885PI4K2B 201/4885PI4K2A 193/4885 |
| US-20250051319-A1 | COMPOUNDS AND USE THEREOF AS HDAC6 INHIBITORS | HDAC6, HDAC9, HDAC1 | PI4KA 3244/4885PI4K2B 2025/4885PI4K2A 2553/4885 |
| US-20250145604-A1 | COMPOUNDS AND USE THEREOF AS HDAC6 INHIBITORS | HDAC6, HDAC9, HDAC1 | PI4KA 3244/4885PI4K2B 2025/4885PI4K2A 2553/4885 |
| US-12421222-B2 | Substituted quinazolines as HDAC6 inhibitors | HDAC6, HDAC9, HDAC1 | PI4KA 3041/4885PI4K2B 2012/4885PI4K2A 2257/4885 |
| US-20120108535-A1 | 2-FLUORINATED RIBOSES AND ARABINOSES AND METHODS OF USE AND SYNTHESIS | SLC2A2, SLC29A2, DERA | PI4KA 3442/4885PI4K2B 2751/4885PI4K2A 2637/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.